[The effect of PSK on laryngeal cancer].
In order to examine effects of PSK (polysaccharide Kureha) on laryngeal cancer, clinical results of 28 patients treated by PSK were compared with those of 31 of the historical control group. Three months after treatments, the PSK group showed a higher cumulative survival rate and better results in immunological parameters such as counts of peripheral lymphocyte, PPD and PHA skin reaction. However, these differences between the PSK group and the control group were not significant statistically, except peripheral leucocyte counts. The side effect was found in one patient who complained of stomach discomfort after applicating PSK.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D011509:Proteoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D014374:Tuberculin Test
D000276:Adjuvants, Immunologic; D010835:Phytohemagglutinins; D011509:Proteoglycans; C010770:polysaccharide-K; D005472:Fluorouracil